An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
229actual
Sites
22
Countries
Australia, France, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-05-30 | actual | When the study began enrolling |
| Primary completion | 2025-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-19 | actual | The whole study's end, after follow-up |
| First posted | 2018-03-08 | actual | When this record first appeared on the registry |
| Results posted | 2026-04-06 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Cancer
Interventions
- Biological: Relatlimab — also filed as BMS-986016
- Biological: Nivolumab — also filed as Opdivo, BMS-936558
- Drug: BMS-986205 — also filed as Linrodostat
- Biological: Ipilimumab — also filed as Yervoy, BMS-734016
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Grade 3/Grade 4 Laboratory Test Results
measured From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Number of Participants With Adverse Events and Deaths
measured From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Number of Participants With Dose Limiting Toxicities
measured From first dose (Day 1) and up to 42 days post first dose
Objective Response Rate (ORR)
measured From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Disease Control Rate (DCR)
measured From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Duration of Response (DoR)
measured From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2023-01-04 · 9.0 MB · Prot_SAP_000.pdf
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed